LLY - AbCellera Biologics: A Buy At Current Prices

• First, AbCellera is a Life Sciences Tools and Services play, not a biotech or pharmaceutical.
• By enabling pharmaceuticals and biotechs to rapidly develop cures, its platform fills a vital gap between innovative ideas and their fast execution.
• One of these cures targets the coronavirus, with another one to be used against its variants currently in development.
• One of the reasons the market is punishing the stock seems to be poor guidance for the second quarter relative to Q1, but there are ingredients to propel longer-term sales higher.
• Also, given the relatively lower expenses required to generate sales, the company should continue to deliver on the profitability metric.

For further details see: